

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-SE 3243	SERIAL NO. 09/211,715
	APPLICANT: Al-Obeidi et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 14, 1998	GROUP 1654

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
FM	✓	4,428,874	01/31/84	Svendson et al.	260	112.5	
FM	✓	4,477,553	10/16/84	Yamamoto et al.	430	192	
FM	✓	4,605,614	08/12/86	Nagasawa et al.	435	13	
FM	✓	5,023,236	06/11/91	Edgington et al.	514	18	
FM	✓	5,189,019	02/23/93	Palladino et al.	514	12	
FM	✓	5,239,058	08/24/93	Vlasuk et al.	530	524	
FM	✓	5,240,913	08/31/93	Maraganore et al.	514	13	
FM	✓	5,328,997	07/12/94	Vlasuk et al.	536	23.5	
FM	✓	5,439,888	08/08/95	Shuman et al.	514	18	

FOREIGN PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION (YES/NO)
FM	✓	EP 0 119 705	26.09.84	EPO			
FM	✓	EP 0 171 270	12.02.86	EPO			
FM	✓	WO 80/00351	06.03.80	PCT			
		WO 93/15756	19.08.93	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

FM	✓	Choay, et al., "Structure-Activity Relationship in Heparin: A Synthetic Pentasaccharide with High Affinity for Antithrombin III and Eliciting High Anti-Factor Xa Activity," <u>Bioch. Biophys. Res. Com.</u> 116(2):492-499 (1983)
FM		Claeson and Aurell, "Small Synthetic Peptides with Affinity for Proteases in Coagulation and Fibrinolysis: an overview," <u>Ann. N.Y. Acad. Sci. (USA)</u> 370:798-811 (1981)
FM		de Feyter, et al., "Acute Coronary Artery Occlusion During and After Percutaneous Transluminal Coronary Angioplasty," <u>Circulation</u> 83(3):927-936 (1991)

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-SE 3243	SERIAL NO. 09/211,715
	APPLICANT: Al-Obeidi et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 14, 1998	GROUP 1654

FM	Detre, et al., "Incidence and Consequences of Periprocedural Occlusion," <u>Circulation</u> 82(3):739-750 (1990)
FM	Dunwiddie et al., "Antistasin, a Leech-derived Inhibitor of Factor Xa," <u>J. Biol. Chem.</u> 264(28):16694-16696 (1989)
FM	Harenberg, "Relation of Antifactor Xa Activity of Heparins and Antithrombotic Efficacy," <u>Haemostasis</u> 18(suppl.3):16-19 (1988)
FM	Hauptmann, et al., "Comparison of the Anticoagulant and Antithrombotic Effects of Synthetic Thrombin and Factor Xa Inhibitors," <u>Thromb. Haemost.</u> 63(2):220-223 (1990)
FM	Hogg and Jackson, "Fibrin Monomer Protects Thrombin from Inactivation by Heparin-Antithrombin III: Implications for Heparin Efficacy," <u>Proc. Natl. Acad. Sci.</u> 86:3619-3623 (1989)
FM	Jorgenson et al., "Angiotensin II Analogs. 6. ¹ Stereochemical Factors in the 5 Position Influencing Pressor Activity. 1," <u>J. Med. Chem.</u> 14(10):899-903 (1971)
FM	Lincoff, et al., "Abrupt Vessel Closure Complicating Coronary Angioplasty: Clinical, Angiographic and Therapeutic Profile," <u>J. Am. Coll. Cardiol.</u> 19(5):926-935 (1992)
FM	Mann and Lorand, "Introduction: Blood Coagulation," <u>Methods in Enzymology</u> 222:1-10 (1993)
FM	Maraganore, "Design and Characterization of Hirulogs: A Novel Class of Bivalent Peptide Inhibitors of Thrombin," <u>Biochemistry</u> 29:7095-7101 (1990)
FM	Maule et al., "RYIRFamide: a Turbellarian FMRFamide-related peptide (FaRP)," <u>Regulatory Peptides</u> 50:37-43 (1994)
FM	Meuleman, "Orgaran (Org 10172): Its Pharmacological Profile in Experimental Models," <u>Haemostasis</u> 22:58-65 (1992)
FM	Nutt, et al., "The Amino Acid Sequence of Antistasin," <u>J. Biol. Chem.</u> 263(21):10162-10167 (1988)
FM	Ofosu, et al., "An Approach to Assigning In Vitro Potency to Unfractionated and Low Molecular Weight Heparins Based on the Inhibition of Prothrombin Activation and Catalysis of Thrombin Inhibition," <u>Thromb. Haemost.</u> 60:193-198 (1988)

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-SE 3243	SERIAL NO. 09/211,715
	APPLICANT: Al-Obeidi et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 14, 1998	GROUP 1654

FM	Ponsati et al., "A Synthetic Strategy for Simultaneous Purification-Conjugation of Antigenic Peptides," <u>Analytical Biochemistry</u> 181:389-395 (1989)
FM	Schaffer, et al., "Antithrombotic Efficacy of Recombinant Tick Anticoagulant Peptide, A Potent Inhibitor of Coagulation Factor Xa in a Primate Model of Arterial Thrombosis," <u>Circulation</u> 84(4):1741-1748 (1991)
FM	Shaw, "Synthetic Irreversible of Coagulation Enzymes," <u>Folia Haematol.</u> 109:33-42 (1982)
FM	Swayze, et al., "Deep Venous Thrombosis in Total Hip Arthroplasty," <u>Orthop. Clin. North. Am.</u> , 23(2):359-364 (1992)
FM	Teitel and Rosenberg, "Protection of Factor Xa from Neutralization by the Heparin-Antithrombin Complex," <u>J. Clin. Invest.</u> 71:1383-1391 (1983)
FM	Tidwell, et al., "Strategies for Anticoagulation with Synthetic Protease Inhibitors. Xa Inhibitors Versus Thrombin Inhibitors," <u>Thromb. Res.</u> 19:339-349 (1980)
FM	Topol, et al., "Use of a Direct Antithrombin, Hirulog, in Place of Heparin During Coronary Angioplasty," <u>Circulation</u> 87(5):1622-1629 (1993)
FM	Turpie, et al., "A Randomized Controlled Trial of a Low-Molecular Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip Surgery," <u>New Eng. J. Med.</u> 315(15):925-929 (1986)
FM	Vlasuk, "Comparison of the In Vivo Anticoagulant Properties of Standard Heparin and the Highly Selective Factor Xa Inhibitors Antistasin and Tick Anticoagulant Peptide (TAP) in a Rabbit Model of Venous Thrombosis," <u>Thromb. Haemost.</u> 65(3):257-262 (1991)
FM	Waxman, et al., "Tick Anticoagulant Peptide (TAP) Is a Novel Inhibitor of Blood Coagulation Factor Xa," <u>Science</u> 248:593-596 (1990)

Form PTO 1449 US Department of Commerce Patent and Trademark Office	ATTY DOCKET NO: P-SE 3243	SERIAL NO. 09/211,715
	APPLICANT: Al-Obeidi et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: December 14, 1998	GROUP 1654

FM	Wessler "Mini-Dose Heparin," <u>Thrombos. Diathes. Hemorrh.</u> 34:718-726 (1978) /		
FM	Yin "Heparin-Accelerated Inhibition of Activated Factor Xa by its Natural Plasma Inhibitor," <u>Bioch. Biophys. Acta.</u> 201:387-390 (1970) /		
<table border="1"> <tr> <td data-bbox="99 669 808 774">EXAMINER <i>F. Morgie</i></td> <td data-bbox="808 669 1498 774">DATE CONSIDERED <i>3/22/00</i></td> </tr> </table>		EXAMINER <i>F. Morgie</i>	DATE CONSIDERED <i>3/22/00</i>
EXAMINER <i>F. Morgie</i>	DATE CONSIDERED <i>3/22/00</i>		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1449.pat